AGIOS PHARMACEUTICALS, INC.: 10-Q filed 2017-05-04
What AGIOS PHARMACEUTICALS, INC. reported in its quarterly report filed 2017-05-04 (fiscal Q1 2017): 23 published measures, 49 facts as tagged in accession 0001193125-17-157874.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-05-04
- Fiscal period
- fiscal Q1 2017
- Accession
- 0001193125-17-157874 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AGIOS PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 557,316,000 | USD | |
| At 2016-12-31 | 619,094,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 307,380,000 | USD | |
| At 2016-12-31 | 358,591,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 200,278,000 | USD | |
| At 2016-12-31 | 160,754,000 | USD | |
| At 2016-03-31 | 39,035,000 | USD | |
| At 2015-12-31 | 71,764,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -66,166,000 | USD | 90 |
| 2016-10-01 to 2016-12-31 | -23,198,000 | USD | 92 |
| 2016-01-01 to 2016-03-31 | -23,198,000 | USD | 91 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 293,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 2,533,000 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | -549,557,000 | USD | |
| At 2016-12-31 | -483,151,000 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 0 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 0 | USD | 91 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 24,139,000 | USD | |
| At 2016-12-31 | 25,337,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 10,734,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 9,107,000 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -67,047,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -23,594,000 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 506,866,000 | USD | |
| At 2016-12-31 | 559,892,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 82,429,000 | USD | |
| At 2016-12-31 | 88,433,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 16,152,000 | USD | |
| At 2016-12-31 | 17,106,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 77,555,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 54,875,000 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 62,732,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 44,038,000 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 42,382,901 | shares | |
| At 2016-12-31 | 42,220,444 | shares |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 2,888,000 | USD | |
| At 2016-12-31 | 1,615,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 25,114,000 | USD | |
| At 2016-12-31 | 32,002,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 12,391,000 | USD | |
| At 2016-12-31 | 10,264,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -66,065,000 | USD | 90 |
| 2016-10-01 to 2016-12-31 | -22,791,000 | USD | 92 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 14,823,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 10,837,000 | USD | 91 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 1,591,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 1,246,000 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -994,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -293,000 | USD | 91 |
Inspect the source
- Entity
- AGIOS PHARMACEUTICALS, INC. / CIK 0001439222
- Captured
- 2026-09-20T09:03:55.707Z
- SEC response SHA-256
645ad0ff8d5c2720a304e1acd1f7ac20706112192f830d9a1be52e84493b37d5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001439222.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))